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Abstract
Introduction Some types of antimicrobial-coated central
venous catheters (A-CVC) have been shown to be cost effective
in preventing catheter-related bloodstream infection (CR-BSI).
However, not all types have been evaluated, and there are
concerns over the quality and usefulness of these earlier
studies. There is uncertainty amongst clinicians over which, if
any, A-CVCs to use. We re-evaluated the cost effectiveness of
all commercially available A-CVCs for prevention of CR-BSI in
adult intensive care unit (ICU) patients.
Methods We used a Markov decision model to compare the
cost effectiveness of A-CVCs relative to uncoated catheters.
Four catheter types were evaluated: minocycline and rifampicin
(MR)-coated catheters, silver, platinum and carbon (SPC)-
impregnated catheters, and two chlorhexidine and silver
sulfadiazine-coated catheters; one coated on the external
surface (CH/SSD (ext)) and the other coated on both surfaces
(CH/SSD (int/ext)). The incremental cost per quality-adjusted
life year gained and the expected net monetary benefits were
estimated for each. Uncertainty arising from data estimates, data
quality and heterogeneity was explored in sensitivity analyses.
Results The baseline analysis, with no consideration of
uncertainty, indicated all four types of A-CVC were cost-saving
relative to uncoated catheters. MR-coated catheters prevented
15 infections per 1,000 catheters and generated the greatest
health benefits, 1.6 quality-adjusted life years, and cost savings
(AUD $130,289). After considering uncertainty in the current
evidence, the MR-coated catheters returned the highest
incremental monetary net benefits of AUD $948 per catheter;
however there was a 62% probability of error in this conclusion.
Although the MR-coated catheters had the highest monetary net
benefits across multiple scenarios, the decision was always
associated with high uncertainty.
Conclusions Current evidence suggests that the cost
effectiveness of using A-CVCs within the ICU is highly
uncertain. Policies to prevent CR-BSI amongst ICU patients
should consider the cost effectiveness of competing
interventions in the light of this uncertainty. Decision makers
would do well to consider the current gaps in knowledge and
the complexity of producing good quality evidence in this area.
Introduction
Catheter-related bloodstream infections (CR-BSIs) increase
health costs and patient morbidity [1], and their prevention has
been the target of national initiatives to create safer and more
efficient healthcare systems [2,3]. These healthcare-acquired
infections are among the group for which the US Centers for
Medicare and Medicaid Services are now able to withhold
payments [4], thereby shifting the cost onto the hospitals
rather than healthcare payers who reimburse the clinical facil-
ities. Given this change in the economic context for infection
control, decision makers are likely to pay more attention to the
cost effectiveness of interventions they employ to reduce rates
of CR-BSI [5].
A-CVC: antimicrobial central venous catheter; CR-BSI: catheter-related bloodstream infection; CH/SSD (ext): chlorhexidine/silver sulfadiazine (exter-
nal coating); CH/SSD (int/ext): chlorhexidine/silver sulfadiazine (internal/external coating); MR: minocycline and rifampicin; QALY: quality-adjusted 
life year; PSA: probabilistic sensitivity analysis; SPC: silver, platinum and carbon.Critical Care    Vol 13 No 2    Halton et al.
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The use of specific types of antimicrobial-coated central
venous catheter (A-CVC) to prevent CR-BSI has been shown
in earlier economic evaluations to be cost-saving and generate
health benefits within the wider healthcare system [6,7]. How-
ever, not all have been evaluated and there are concerns over
the quality of these evaluations and the usefulness of their find-
ings for real-world decision making [8].
Problems with the existing economic evidence contribute to
the ongoing uncertainty about the use of A-CVCs. First, the
relative cost effectiveness of the different types of A-CVC is
unknown as none of the previous evaluations compared all
available types. Second, recent epidemiological evidence [1]
suggests earlier evaluations may have overestimated the
attributable mortality and length of stay associated with CR-
BSI, and these were key drivers of the results [8]. Third, the
excess length of stay due to infection is a major source of cost
savings and the dollar value given to each bed day released
will depend on the preferences of the decision maker. They
cannot be directly observed and require careful elicitation, and
the valuation may change depending on who is making the
decision. To date there has been no discussion as to how
these value judgments are derived, creating another subtle
source of uncertainty in the results of the earlier evaluations.
There is continued uncertainty among clinicians over which, if
any, A-CVC to use. Clinical guidelines recommend their use
only in specific circumstances [9], and evidence suggests that
the uptake of these technologies remains patchy [10,11]. The
purpose of this study is to evaluate the cost effectiveness of
adopting A-CVCs to prevent CR-BSI in Australian intensive
care units (ICUs). We considered all available catheter types,
used updated estimates of the consequences of infection, and
explored how uncertainty can impact the adoption decision.
By doing so, we provide a deeper analysis of this infection
control decision that will support those working in this clinical
area.
Materials and methods
We undertook an economic evaluation to identify the cost
effectiveness of triple-lumen A-CVCs for standard use in Aus-
tralian adult ICUs. We considered all commercially manufac-
tured A-CVCs sold in Australia: minocycline and rifampicin
(MR)-coated catheters; silver, platinum and carbon (SPC)-
impregnated catheters; and two chlorhexidine and silver sul-
fadiazine-coated catheters; one coated on the external surface
(CH/SSD (ext)) and the other coated on both catheter sur-
faces (CH/SSD (int/ext)). The baseline comparator was
uncoated polyurethane catheters.
Model development
Clinical events used to structure the model were identified in
conjunction with intensive care clinicians. Clinical and eco-
nomic events under a healthcare perspective were identified
and organized into Markov states (Figure 1). Patients were
assumed to receive a CVC on entry to ICU, and over subse-
quent daily cycles either retained their catheter, had it
removed, or developed a CR-BSI [12]. Patients faced an
underlying risk of mortality whilst in the ICU and a further risk
should they develop CR-BSI. The surviving cohort was mod-
eled for the remainder of their lifetime in monthly cycles, mov-
ing to yearly cycles 1 year after discharge.
ICUs were assumed to have existing optimal infection control
procedures in place. Multiple catheterizations, catheters
inserted or removed outside the ICU and future catheteriza-
tions were excluded. We did not model catheter colonization,
as this event alone carries no health or economic conse-
quences, or anaphylactic reaction to the CH/SSD catheters
[13], as this event is rare. The effectiveness of all catheters
and the consequences of CR-BSI were considered independ-
ent of patient age or disease severity and causative microor-
ganisms. Treatment success was considered to be final and
we did not model recurrence of infection. Economic costs
were measured in 2006 Australian dollars and health out-
comes in quality-adjusted life years (QALYs). Costs and health
outcomes relating to the original ICU experience but occurring
in future time periods were discounted at a rate of 3%. In line
with recommendations [14] we did not attempt to model future
access to healthcare.
Framework for evaluation
The strong evidence that CR-BSI increases of length of stay in
the ICU and general wards suggests that health care costs will
vary between catheters if they differ in effectiveness at pre-
venting infection. Conversely, there is relatively weak evidence
for the causal relationship between CR-BSI and mortality; this
implies a tenuous difference in health outcomes for different
catheter choices. One approach is to assume that health out-
comes (measured in QALYs) are the same for all catheter
types and so economic evaluation could be simplified to a
cost-minimization analysis. This approach to making decisions
Figure 1
Markov model used for the evaluation Markov model used for the evaluation.Available online http://ccforum.com/content/13/2/R35
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is, however, unhelpful [15]. Studies have not shown an
absence of effect; rather, they have been unable to show a sta-
tistically significant positive effect between CR-BSI and mor-
tality. The best interpretation is that we are uncertain about any
relationship between CR-BSI and mortality. Thus we chose to
use cost effectiveness analysis (CEA) and explore the impact
of the uncertainty about attributable mortality (and other model
parameters) on our conclusions.
Data sources
Parameters used in the model are shown in Table 1. Where
estimates were obtained from the literature, relevant articles
were identified via reproducible searches in the Medline data-
base to 1 January 2008, and earlier economic evaluations of
strategies to prevent CR-BSI were reviewed. Bibliographic
details for all relevant studies identified in these searches are
provided in Additional data file 1.
The context of the evaluation was a level 3 (tertiary referral)
ICU [16]. Based on a 4-year dataset of 11,790 ICU admis-
sions we assumed that 17% would receive a CVC [17]. This
catheterized cohort had a mean age of 62.7 (standard devia-
tion (SD) 17.2) years, mean Acute Physiology and Chronic
Health Evaluation II score of 17.1 (SD 8) and 65% were male.
These estimates are comparable to those reported for 46 pub-
licly funded ICUs by the Australia and New Zealand Intensive
Care Society [18]. Baseline risk of ICU mortality was 9.8%
and 16.1% by hospital discharge.
Probability of CR-BSI was modeled as increasing in stepwise
increments with duration of catheterization [19] to give an
overall incidence of infection of 2.5%. This was observed in
routine surveillance data collected from February 2001 to
December 2005 in 21 medium-to-large public hospitals in
Queensland, Australia [20]. Estimates for the effectiveness of
each type of A-CVC were taken from a single systematic
review, chosen from amongst 14 identified because it pro-
vided relative risks separately for each type of coating [21].
The relative risk of hospital mortality associated with CR-BSI
was estimated to be 1.06 [1]. Given a 9.8% baseline risk, this
corresponds to an absolute increase in mortality of just under
1%. Excess length of stay due to infection was estimated at
2.4 ICU and 7.5 general ward days [22]. These values were
chosen from amongst 19 estimates of attributable mortality
and 11 estimates of increases to length of stay identified in a
literature search, as they were of high quality (judgment based
on Samore and Harbarth [23]) and the population was compa-
rable to our ICU context.
Annual mortality rates for 15 years post ICU discharge were
taken from a data linkage study [24] that followed over 10,000
Australian ICU patients. Subsequent life expectancy was
based on Australian Institute of Health and Welfare published
age-specific mortality rates [25]. To calculate QALYs, prefer-
ence based utility weights were assigned to cycles spent in
the ICU and 6 months immediately post discharge. Although
evidence suggests that quality of life may be reduced in some
survivors for a longer period post discharge [26], information
on this was unavailable for our population. Therefore, to be
conservative, life expectancy for those surviving beyond this
period was adjusted using Australian population quality of life
norms [27]. In all, 14 studies estimated utility weights for ICU
patients. Values were used from the study [28] with participant
demographics most similar to our cohort. This study used an
instrument (the EQ-5D) shown to predict weights similar to the
Australian Quality of Life instrument used to derive population
norms [29]. No further quality of life decrement was attributed
to CR-BSI.
All costs were valued at 2006 prices, using the Australian
Bureau of Labor Statistics Consumer Price Index [30] to
adjust where necessary. Consumable costs in the evaluation
included the price of a catheter, diagnosis costs of one cathe-
ter tip and two blood cultures per CR-BSI and treatment costs.
Treatment costs were a weighted average of the cost of stand-
ard regimens for causative organisms observed within the sur-
veillance system: 2 weeks vancomycin, 10 days ticarcillin, 4
weeks fluconazole. Prices for all consumables reflect those
faced by Queensland Health decision makers.
The economic value of bed days released by the prevention of
CR-BSI was assessed from two alternate perspectives. A
broader perspective of the healthcare decision maker who
manages waiting lists, and for whom there is a real economic
benefit in releasing a bed day for another patient to occupy,
and a narrower perspective of a manager working within an
ICU or hospital. Values to represent the broader perspective
were obtained for an ICU bed day from a detailed costing
study of an Australian ICU [31] and for a general ward bed day
from an earlier economic evaluation which considered spend-
ing patterns for Australian public hospital services [32]. These
estimates of AUD $3,021 and AUD $843 represent short-run
average costs calculated by dividing total costs (that is, fixed
and variable costs) by the total bed days for a 12-month
budget period. They may or may not approximate the eco-
nomic opportunity cost of losing a bed day to CR-BSI. The
alternate narrow perspective value considered only the varia-
ble cost per bed day. Variable costs are the cash savings that
budget holders within the hospital can recoup if bed days are
not used; they include items such as fluids, dressings and
pharmaceuticals. These costs are meaningful to hospital
administrators, who cannot avoid fixed operating costs even if
infections reduce [33]. An important caveat for the narrow per-
spective costs is that they decrease over the duration of ICU
stay [34]; we assumed it would be later, less costly, days
released by preventing infection and adjusted our baseline
estimates based on the daily pattern of variable costs reported
in a similar patient population [34], to give estimates of AUD
$335 for ICUs and AUD $101 for general wards.Critical Care    Vol 13 No 2    Halton et al.
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Table 1
Parameter estimates used in the model
Parameters Baseline estimate Variation (SEM) Distribution Source Level of evidence
Infection-related events:
Probability of CR-BSI Modeled in stepwise incrementsa Beta Database 1
RR mortality (CR-BSI) 1.06 0.18 Log normal [1] 2
Extra days in the ICU 2.41 0.83 Log normal [22] 2
Extra days on hospital ward 7.54 1.81 Log normal
Effectiveness A-CVCs (RR):
SPC 0.54 0.62 Log transformed normal [21] 1 +
CH/SSD (ext) 0.66 0.17
CH/SSD (int/ext) 0.70 0.43
MR 0.39 0.43
Baseline probabilities of mortality:
ICU mortality 0.098 0.002 Beta Dataset 2
Hospital mortality 0.069 0.001 Beta Dataset 2
Annual mortality post 
discharge
Year 1 0.050 0.002 Beta [24] 2
Years 2 to 3 0.027 0.002
Years 4 to 5 0.028 0.002
Years 6 to 10 0.037 0.003
Years 11 to 15 0.042 0.003
Underlying annual 
mortality
45 to 64 years 0.004 - NA [25] 1
65 to 84 years 0.030 -
85 + years 0.140 -
Utilities:
Utility ICU 0.66 0.27 Beta [28] 3
Utilities population 
norms
50 to 59 years 0.80 0.22 Beta [27] 3
60 to 69 years 0.79 0.19
70 to 79 years 0.75 0.25
80 + years 0.66 0.29
Costs, 2006 AUD:
ICU bed day 3,021 - NA [31] 4
Hospital bed day 843 - NA [32] 3
Diagnostics CR-BSI 101.70 - NA Database 1
Treatment CR-BSI 591.30 - NA Database 1
Additional cost per 
catheter
SPC 22.36 - NA Database 1
CH/SSD (ext) 11.64 -
CH/SSD (int/ext) 41.35 -
MR 59.36 -
aAvailable on request from the authors.
A-CVCs, antimicrobial central venous catheters; CH/SSD, chlorhexidine silver sulfadiazine; CR-BSI, catheter related bloodstream infection; ICU, 
intensive care unit; int/ext, internally and externally coated; MR, minocycline and rifampicin; RR, relative risk; SPC, silver, platinum and carbon.Available online http://ccforum.com/content/13/2/R35
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Model evaluation
Model evaluation was performed in three stages. First, uncer-
tainty in the cost effectiveness evaluation was ignored and a
single value was used for each model parameter. The incre-
mental change in costs (C) and QALYs (E) were estimated
for each type of A-CVC and incremental cost effectiveness
ratios (ICERs) were calculated (C/E). A catheter type was
considered to be cost-saving if greater health benefits and
reduced costs were achieved as compared to uncoated cath-
eters, and considered cost effective if the ICER was below a
threshold willingness-to-pay ratio () of AUD $40,000 per
QALY. This threshold was chosen based on an analysis of
positive reimbursement decisions made by the Pharmaceuti-
cal Benefits Advisory Committee, Australia [35].
Second, probabilistic sensitivity analysis (PSA) [36] was used
to capture uncertainty in the current data. The error in each
estimate (parameter) used in the model, as described by its
standard error, was characterized using an appropriate proba-
bility distribution (Table 1), except costs that were assumed
known in the context of the evaluation. A total of 10,000 Monte
Carlo simulations were run; in each one a new value was
drawn for each parameter from within the distribution speci-
fied. The results of each simulation were presented as the
monetary net benefits generated by each catheter type. Mon-
etary net benefits were used as they are linear and have
improved properties as compared to ICERs for decision mak-
ing [37]. Although we expressed net benefits in monetary
terms, this is not a cost-benefit analysis. Monetary net benefits
were calculated by valuing incremental QALYs generated by
the A-CVC at $40,000 each (the willingness-to-pay threshold)
and then subtracting incremental costs (that is, NB = ( × E)-
C).
The average monetary net benefit across the 10,000 simula-
tions was calculated for each catheter type along with 95%
confidence intervals (CIs). Given the economic objective of
maximizing benefits given scarce resources, the optimal deci-
sion was defined as the catheter associated with the highest
average monetary net benefit; choosing anything else would
incur an opportunity cost. The likelihood of error in this conclu-
sion was also calculated. The proportion of simulations in
which a catheter returned the highest monetary net benefit
represents the probability that catheter type is optimal; 1
minus this proportion represents the probability that the cath-
eter does not return the highest monetary net benefits, but
instead incurs a cost, and the decision is incorrect. Table 2
illustrates this interpretation using hypothetical data for two
novel treatments compared to standard practice.
Third, we used scenario analysis to explore uncertainty intro-
duced by the fact that some data used in the model was of low
quality. Using a modified version [38] of the potential hierar-
chies of data sources for economic evaluations [39], we iden-
tified data of medium and low quality (Table 1); defined as
scoring level 3 or below. For each parameter with medium/low
quality data we assigned a plausible alternate value and re-
evaluated the model. The dollar value given to the opportunity
cost of bed days was changed to reflect the broader and nar-
rower perspectives of different decision makers. A higher esti-
mate for attributable mortality of 15% was used, which is
comparable to that assumed in earlier economic evaluations of
A-CVCs. Higher estimates of the extension to stay of 6.5 days
on the ICU and 6 days on the general ward due to CR-BSI
were used. All utility weights for health states were removed,
which is equivalent to using unadjusted life years rather than
QALYs. The final scenario reflected the fact that the absolute
effectiveness and cost effectiveness of A-CVCs will be
dependent on starting rates of infection [40]; lower (0.8%)
and higher (5.0%) rates were used to cover the range reported
from individual hospitals within the surveillance dataset. In
each scenario we reran an analysis to recalculate the monetary
net benefit for each catheter type and so identify the optimal
catheter.
Results
The results of the first analysis, without uncertainty, showed all
four types of A-CVC were cost-saving relative to uncoated
catheters (Figure 2). The antibiotic-coated catheter (MR)
achieved the greatest health benefits and lowest costs and
dominated the use of uncoated and the three antiseptic-
coated catheter types (SPC, CH/SSD (ext) and CH/SSD (int/
ext)). Compared to uncoated catheters, the use of MR cathe-
ters avoided 15 infections and generated 1.6 QALYs per
1,000 catheters placed. The MR catheters also released 32
ICU bed days and 95 general ward bed days and achieved
cost savings of AUD $130,000 per 1,000 catheters (Table 3).
The second analysis based on PSA to incorporate uncertainty
indicated that at a willingness-to-pay threshold of AUD
$40,000 per QALY the average monetary net benefits esti-
mated for each catheter type were very similar with substantial
overlap in the 95% CIs (Table 3). Figure 3 shows the distribu-
tion of monetary net benefits for the MR, CH/SSD (ext) and
uncoated catheters, for clarity the other catheter types have
been omitted as their distributions lie over those presented.
The MR catheters returned the highest monetary net benefits
and represented the optimal choice given current information.
They are associated with expected incremental monetary net
benefits of AUD $948 per catheter relative to retaining the
uncoated type (that is, the average monetary net benefits for a
MR catheter, AUD $391,612, minus those for an uncoated
catheter, AUD $390,664); however the probability of error in
this decision is 62% (Table 4).
For the third analysis, using alternate scenarios for key param-
eters, the MR catheters maximized monetary net benefits in all
cases. However, the probability of error in this decision was
consistently high and the 95% CIs for the estimated monetary
net benefits associated with these catheters were large (TableCritical Care    Vol 13 No 2    Halton et al.
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4). The lowest estimate of monetary net benefits arose when
bed days were valued at variable cost savings only (that is, the
narrow hospital perspective). In this scenario, monetary net
benefits associated with MR catheters would be just under
AUD $200 per catheter relative to uncoated catheters
because the catheters were no longer cost saving instead
requiring an increase in expenditure to produce health benefits
(Table 4). The highest estimate of monetary net benefits was
obtained when an attributable mortality of 15% was assumed.
In this scenario, MR catheters were cost-saving and generated
high monetary net benefits of nearly AUD $2,441 per catheter
relative to retaining uncoated catheters. Scenarios that
returned higher estimates of expected monetary net benefits
were associated with less uncertainty. Under the high mortality
scenario the probability that choosing MR catheters as optimal
was incorrect fell to 46%, whilst in the low bed days scenario,
where expected monetary net benefits were low, the error
probability in this decision was 76%.
Discussion
Our evaluation suggests any decision regarding the use of A-
CVCs in ICU patients is uncertain. The findings from the first
analysis, which do not consider uncertainty, concur with exist-
ing economic evidence [6,7]. This shows that, for all four types
of antimicrobial catheter, health gains will be accompanied by
cost savings. Given the assumption of a low attributable mor-
tality and a low rate of infection, expected health gains are min-
imal and the decision is driven by the change in costs. Most of
these costs represent the value of obtaining increased capac-
ity within the ICU, rather than cash savings. Nevertheless, the
results of the first analysis imply a decision not to adopt these
catheters will harm patients by reducing their health status and
increasing their risk of mortality and, simultaneously, waste
resources within the healthcare system.
Our second analysis, using PSA, introduces the uncertainty
associated with the decision. Based on current information,
the MR catheters are the optimal decision because they return
the highest net monetary benefits relative to all other catheter
types. However, the probability of error in this conclusion is
high, at 62%. Our third analysis shows that MR catheters
remain the optimal decision across a range of scenarios and
quantifies how uncertainty in this decision varies. Uncertainty
is lower for scenarios where decision makers believe that
attributable mortality is high, where they value bed days highly,
or where the starting infection rate is high. This finding fits with
conclusions from a recent meta-analysis that suggests that
antimicrobial catheters will return a higher treatment benefit
when infection rates are high [40], and provides support for
current guidelines which recommend reserving their use for
settings with high infection rates [9]. However, even in these
scenarios the probability that this conclusion is wrong, and the
MR catheters are not optimal, does not reduce below 46%.
Table 2
Monetary net benefits for a hypothetical evaluation comparing two novel treatments to standard practice
Standard practice Treatment A Treatment B Optimal choice
Simulation 1 140 150 160 B
Simulation 2 100 110 120 B
Simulation 3 110 100 100 Standard
Simulation 4 100 150 130 A
Simulation 5 130 120 110 Standard
Average expected net benefit 116 126 124 Standard/A/B = 40%/20%/40%
Results are expressed as monetary net benefits, each simulation is equally likely to be 'true'. Treatment A is associated with the highest expected 
net benefit (AUD $126), but because the distribution of monetary net benefits is skewed, it is preferred in only 20% of samples. Treatment A is 
therefore optimal, but the error probability associated with this choice is 80%. This probability is substantially higher than the 5% used for tests of 
statistical significance. The choice to remain with standard practice still carries a 40% probability of not returning the highest monetary net 
benefits and could be expected to incur economic costs of AUD $10 (AUD $126 minus AUD $116). The alternative with the highest monetary 
net benefit is the optimal decision, but that decision can be highly uncertain.
Figure 2
Cost effectiveness of antimicrobial central venous catheters in the  baseline analysis (results per 1,000 catheters) Cost effectiveness of antimicrobial central venous catheters in the 
baseline analysis (results per 1,000 catheters). CH/SSD (int/ext) = 
internally and externally coated chlorhexidine and silver sulfadiazine 
catheters; CH/SSD (ext) = externally coated chlorhexidine and silver 
sulfadiazine catheters; SPC = silver, platinum and carbon impregnated 
catheters; MR = minocycline and rifampicin coated catheters; QALY = 
quality-adjusted life year.Available online http://ccforum.com/content/13/2/R35
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Interpreting the results of cost effectiveness analyses under
uncertainty requires decision makers to think beyond conven-
tional error rates as used in statistical analysis. Decision mak-
ers looking to maximize health returns from their budget should
choose between these catheters by selecting the option with
the highest monetary net benefits. Given the current evidence,
MR catheters should be chosen even if the probability of error
in this conclusion exceeds the standard level of 5% used to
define statistical significance. The justification is that a deci-
sion not to use them in favor of uncoated catheters would
impose economic costs, arising from average monetary net
benefits foregone, of AUD $948 per catheter [41] (AUD
$391,612 minus AUD $390,664). This conclusion should
lead to rapid and sustained uptake of the technology [5], yet
their use appears to be limited despite earlier estimates of
these catheters being cost effective [6,7]. We suggest that
uncertainty over this cost effectiveness evidence may be partly
responsible.
Studies have shown that decision makers are heavily influ-
enced by uncertainty [35,42]. Presenting decision makers
with an estimate of uncertainty in the results of an economic
evaluation is important for the following reasons: it makes the
current state of knowledge about the decision explicit and
quantifies confidence (or lack of) in conclusions; it allows them
to weigh the cost effectiveness results against other relevant
considerations in the adoption decision including their own
attitude to risk; and it provides an indication of the value of
conducting further research to reduce uncertainty.
Two aspects to uncertainty are important: the probability of
making the wrong choice and the potential consequences of
getting it wrong. Both elements are required; a decision with a
5% probability of being wrong may still be perceived as uncer-
tain if the consequences are very large. Decision makers tend
to be risk averse. Rather than being focused solely on maximiz-
ing health returns, they are also concerned with interventions
that have the potential to result in harmful outcomes. If there is
no potential for harm then decision makers may be happy to
accept a new intervention with a high but uncertain benefit.
But where the potential for harm is perceived to be high, an
existing intervention with a lower benefit may be preferred.
Antimicrobial catheters are perceived to carry a risk of a
number of negative outcomes that are likely to deter from their
introduction, including the potential for a loss of focus on
hygiene procedures. There has also been discussion [43] that
MR catheters may select for resistant organisms, with higher
morbidity and costs [44]. This negative could outweigh poten-
tial short-term benefits from these catheters [45]. An absence
of clear evidence [46] makes it difficult to quantitatively incor-
Table 3
Economic evaluation of antimicrobial central venous catheters: incremental costs and health outcomes under baseline analysis
Catheter type Infections avoideda ICU bed days 
releaseda
Costs saveda (2006 
AUD)
QALYs gaineda ICER Average monetary 
net benefitsb (95% 
confidence interval)
Uncoated 390,664 (371,984 to 
408,416)
CH/SSD (ext) 8.4 18.1 $93,281 0.91 Dominated 391,212 (372,736 to 
408,687)
CH/SSD (int/ext) 7.4 15.9 $51,126 0.80 Dominated 391,030 (372,467 to 
408,574)
SPC 11.4 24.6 $120,062 1.23 Dominated 391,206 (372,687 to 
408,772)
MR 15.2 32.8 $130,289 1.64 Cost-saving 391,612 (373,159 to 
408,861)
aResults presented per 1,000 catheters; bMonetary net benefits reported per catheter assuming a willingness-to-pay for a QALY of AUD $40,000.
CH/SSD, chlorhexidine silver sulfadiazine; ICER, incremental cost effectiveness ratio; ICU, intensive care unit; int/ext, internally and externally 
coated; QALY, quality-adjusted life year; MR, minocycline and rifampicin; SPC, silver, platinum and carbon.
Figure 3
Distribution of monetary net benefits associated with selected catheter  types Distribution of monetary net benefits associated with selected catheter 
types. CH/SSD (ext) = externally coated chlorhexidine and silver sul-
fadiazine catheters; MR = minocycline and rifampicin coated catheters; 
QALY = quality-adjusted life year.Critical Care    Vol 13 No 2    Halton et al.
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porate this risk into an economic evaluation [47] but it is an
important consideration in the adoption decision.
Decision makers deciding whether to use antimicrobial cathe-
ters also have a second choice: whether to collect more infor-
mation to reduce uncertainty in their choice [48]. Value of
information analysis [41] can be used to estimate the expected
monetary net benefits arising from collecting new information
and compare this to the anticipated research costs to indicate
whether the research is justifiable. It has been suggested fur-
ther trials of antimicrobial catheters should be undertaken
[43]. Due to the relative rarity of infection these will require a
large sample size and the involvement of multiple institutions
[43], making them an expensive proposition. Estimating the
expected monetary net benefits from a trial would indicate if
this is the best way to spend research dollars.
Some important sources of uncertainty have been explored in
these analyses, but there are other uncertain elements in this
decision that have not been explicitly examined. There is evi-
dence the relative effectiveness of A-CVCs, as compared to
uncoated catheters, varies according to duration of catheteri-
zation [49] and causative organism [50], and there have been
reports of toxicity associated with use of particular types of
catheter [13]. However, a lack of data about these concerns
both generally, and in relation to each specific coating, meant
we were unable to model their impact. If these aspects reduce
the effectiveness of any of the catheter types then its cost
effectiveness would also be reduced. Alternatively there may
be specific subgroups of patients for whom the cost effective-
ness of these catheters can be determined with greater cer-
tainty. We did not test assumptions about life expectancy and
quality of life in ICU survivors, although these will not alter con-
clusions about which catheter is optimal as all types will be
affected equally.
This evaluation, like those reported in earlier studies, is based
on a simplified version of a complex decision. It did not include
intangible benefits to reduced infection rates, including the
increases to clinical morale and public confidence in the
healthcare system demonstrated by the national campaigns to
reduce rates of CR-BSI [2] and forming part of the rationale for
the introduction of the Deficit Reduction Act [4]. Decision
makers often consider a wider range of outcomes when decid-
ing on the adoption of a new technology [35,42] and clearly
the economic value in reducing infection rates goes beyond
the capacity released within hospitals. Valuing these intangible
outcomes may improve the representation of the economics of
preventing infection, but it would be difficult to achieve. It has
been suggested that MR-coated catheters are difficult to
insert [6], making them unpopular amongst clinicians, but data
comparing failure rates for insertion are not available in order
to incorporate this cost. Finally, recent research has shown
that improving catheter care by intervention 'bundles' is a
highly effective way to reduce rates of CR-BSI [51]. In an eval-
uation comparing 'bundles' with antimicrobial catheters, it may
be that the former would dominate. This is not evaluated here
and deserves rigorous exploration rather than hypothesizing.
Conclusions
Antimicrobial catheters have been available as a means of pre-
venting CR-BSI in the ICU for two decades. Although earlier
studies have indicated these devices are cost saving, the find-
ings of this evaluation represent a deeper analysis of the deci-
Table 4
Optimal choice of catheter under uncertainty, given different data scenarios
Scenario Optimal catheter choice Incremental outcomes with no 
uncertainty
Average incremental monetary net 
benefits given uncertaintyb
Catheter type Probability of 
error
Costsa QALYsa Mean 95% Confidence 
interval
Baseline MR 0.62 - $130,289 1.64 948 -106 to 3,792
Low bed day ($335 
ICU/$101 ward)
MR 0.76 + $28,257 1.64 191 -348 to 1,317
High mortality (15%) MR 0.46 - $106,223 26.65 2,441 116 to 8,516
No utility weights used MR 0.62 - $130,289 2.33 1,042 -166 to 3,961
Increased length of 
stay (6.5 days ICU/6 
days ward)
MR 0.56 - $282,038 1.64 1,239 -57 to 4,795
Low infection rate 
(0.8%)
MR 0.75 - $1,972 0.53 325 -71 to 1,283
High infection rate 
(5.0%)
MR 0.56 - $314,400 3.23 1,725 -139 to 6,455
aRelative to uncoated catheters and per 1,000 catheters; bMonetary net benefits reported per catheter relative to uncoated catheters assuming a 
willingness-to-pay for a QALY of AUD $40,000.
ICU, intensive care unit; QALY, quality-adjusted life year.Available online http://ccforum.com/content/13/2/R35
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sion than previously available that will help decision makers in
any setting considering adopting A-CVCs judge the cost
effectiveness of these devices. We have shown that the cost
effectiveness of these catheters is uncertain, and are not sur-
prised that infection control decision makers are reticent about
using antimicrobial catheters despite the economic evidence.
Failure to consider uncertainty generates overly simplistic
results and creates skepticism amongst decision makers
using them to guide infection control policy. Value of informa-
tion analyses may suggest where research to reduce this
uncertainty should focus, but in the meantime, legislation
based on the economics of infection control would do well to
consider the complexity of producing good quality evidence in
this area.
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